Signaling inhibitors in the treatment of prostate cancer

Investigational New Drugs

Volumn 20, Issue 2, 2002, Pages 159-172

  Hudes, Gary R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Androgen receptor; Growth factors; Prostate cancer; Signal transduction

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 7 HYDROXYSTAUROSPORINE; ANDROGEN RECEPTOR; BRYOSTATIN 1; CEP 701; CETUXIMAB; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; GEFITINIB; GROWTH FACTOR RECEPTOR; IMATINIB; ISIS 3521; L 778123; LEFLUNOMIDE; LONAFARNIB; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SOMATOMEDIN; TIPIFARNIB; TRASTUZUMAB; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; ARTICLE; CANCER THERAPY; CASTRATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0036282857     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015678427111     Document Type: Article

References (120)

1. Cancer statistics
2. Natural history of progression after PSA elevation following radical prostatectomy
3. Signaling through scaffold, anchoring, and adaptor proteins
4. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization
5. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor
6. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor
7. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways
8. Activation of the human androgen receptor through a protein kinase A signaling pathway
9. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the Her-2/neu tyrosine kinase
10. From Her2/Neu signal cascade to androgen receptor and its co-activators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
11. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor 1, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines
12. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway
13. Her-2-neu expression and progression toward androgen independence in human prostate cancer
14. Androgen receptor - An update of mechanisms of action in prostate cancer
15. Expression of androgen receptor co-regulatory proteins in prostate cancer and stromal-cell culture models
16. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA 70, in human prostate cancer DU145 cells
17. β-catenin affects androgen receptor transcriptional activity and ligand specificity
18. Rapid signaling by androgen receptor in prostate cancer cells
19. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor a in the progression of prostatic neoplasms
20. Rational basis for trk inhibition therapy for prostate cancer
21. Cell cycle-independent death of prostate adenocarcinoma is induced by the tyrosine kinase inhibitor CEP-751 (KT6587)
22. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays
23. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer
24. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas
25. Dysregulated expression of growth factors and their receptors in the development of prostate cancer
26. Insulin-like growth factors and prostate cancer
27. Peptide growth factors and prostate cancer: New models, new opportunities
28. Response of prostate cancer cells to peptide growth factors: Transforming growth factor-b
29. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor, shows evidence of good tolerability and activity: Final results from a Phase I study
30. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types: Evidence of activity and good tolerability
31. Dose and schedule duration escalation of the epidermal growth factor receptor tyrosine kinase inhibitor CP-358,774: A Phase I and pharmacokinetic study
32. Phase I dose escalation study of epidermal growth factor receptor tyrosine kinase inhibitor CP-358,774 in patients with advanced solid tumors
33. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
34. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p 27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells
35. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without chemotherapy
36. Antitumor effect and potentiation of cytotoxic drug activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
37. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
38. Signal transduction by the neurotrophin receptors
39. Nerve growth factor: A tale of two receptors
40. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)
41. The tyrosine kinase inhibitors CEP-751 (KT-6587) and CEP-701 (KT-5555) lead to apoptosis in prostate cancer cells via the elevation of intra-cellular free calcium and inhibition of the PI-3Kinase/PKB pathway
42. Phase I study of oral CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor
43. Mechanism of action and in vivo role of platelet-derived growth factor
44. PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor
45. PDGF-D, a new protease-activated growth factor
46. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor
47. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor α and β receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas
48. A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer
49. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(Trifluororomethyl)-phenyl]5-meth ylisoxazole-4-carbamide
50. A Phase I and pharmacologic study of the tyrosine kinase inhibitor SU 101 in patients with advanced solid tumors
51. Signaling inhibitors in the clinic: New agents and new challenges
52. Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies
53. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
54. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
55. Blockade of PDGF-R signaling by ST1571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice
56. Ras oncogenes in human cancer. A review
57. Activated ras alleles in human carcinoma of the prostate are rare
58. Infrequent RAS oncogene mutations in human prostate cancer
59. Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas
60. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
61. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
62. Protein prenylation: Key to ras function and cancer intervention?
63. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
64. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
65. A Phase I trial of ISI5 2503, an antisense inhibitor of H-ras, administered by a 24-hour weekly infusion to patients with advanced cancer
66. Ras protein fanesyltransferase: A strategic target for anticancer therapeutic development
67. Non-ras targets of farnesyltransferase inhibitors: Focus on rho
68. K- and N-ras are geranyl-geranylated in cells treated with farnesyl protein transferase inhibitors
69. Direct demonstration of geranylageranylation and farnesylation of Ki-ras in vivo
70. Characterization of HaRas, N-Ras, Ki-Ras4A and Ki-Ras 4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type 1
71. Farnesyltransferase inhibitors and cancer treatment: Targeting simply ras?
72. Phase I pharmacokinetic study of famesyl protein transferase inhibitor R 115777 in advanced cancer
73. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule
74. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor R115777
75. Farnesyltransferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
76. ras function and protein farnesylation, in human prostate and breast carcinoma cell lines
77. Intracellular signaling by hydrolysis of phospholipids and activation on protein kinase C
78. Requirement of Ras-GTP-Raf complexes for activation to Raf- 1 by protein kinase C
79. Role of Diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-I protein kinase
80. 12(S)-HETE enhancement of prostate tumor cell invasion: Selective role of PKCa
81. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer
82. Dephosphorylation of activated protein kinase C contributes to downregulation by bryostatin
83. The in vivo effect of bryostatin-1 on paclitaxe-induced tumor growth, mitotic entry, and blood flow
84. Differential effects of bryostatin I and phorbol ester on human breast cancer cell lines
85. Successful treatment of murine melanoma with bryostatin- 1
86. Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells
87. Preclinical pharmacology of the natural product anticancer-agent bryostatin- 1, an activator of protein kinase C
88. Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo
89. A Phase I study of intravenous bryostatin 1 in patients with advanced cancer
90. A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion
91. A Phase II study of bryostatin 1 in metastatic malignant melanoma
92. A Phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer
93. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma
94. Phase II trial of bryostatin 1 in patients with relapsed low-grade nonHodgkin's lymphoma and chronic lymphocytic leukemia
95. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: A new therapeutic strategy
96. Phase I trial of weekly sequential bryostatin-1, cisplatin, and paclitaxel in patients with advanced solid tumors
97. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms
98. Phase I and pharmacokinetic study of PKC 412, an inhibitor of protein kinase C
99. Implication of cell kinetic changes during the progression of human prostatic cancer
100. Cell kinetic measurements in prostate cancer
101. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phophoinositide 3-kinase/AKT pathway
102. Mechanisms and consequences of activation of protein kinase B/AKT
103. PI3-kinases: Role in signal transduction
104. Structural assets of a tumor suppressor
105. Dual role of phosphatidylinositol-3,4,5-triphosphate in the activation of protein kinase B
106. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor
107. Inactivation of the tumor suppressor PTEN/MMAC 1 in advanced human prostate cancer through loss of expression
108. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts
109. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
110. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27kip1 expression
111. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN
112. Focal adhesion kinase, rapl, and transcriptional induction of vascular endothelial growth factor
113. Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/phosphatidylinositol 3- kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
114. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints
115. A signaling pathway to translational control
116. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway
117. The mRNA 5′ cap-binding protein e1F4E and control of cell growth
118. The effect of CCI-779, a novel macrolide antitumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo
119. CCI-779, an ester analogue of rapamycin that interacts with PTEN/P13 kinase pathways: A Phase I study utilizing a weekly intravenous schedule
120. Phase I and pharmacological study of CCI-779, a cell cycle inhibitor